In the quiet machinery of the US Federal Register, a proposal has taken shape that would let compounding pharmacies prepare six peptides the Food and Drug Administration has never approved. It is a moment that sits at the meeting point of two old human impulses: the wish to heal faster and look younger, and the long-standing discipline of testing what we put into our bodies before we trust it. Its origin inside the health secretary's office rather than the regulator meant to shape such rules marks it as a choice of leadership, not a slow consensus, and it arrives as the wider world already sel
RFK Jr. Plan Would Let Compounding Pharmacies Prepare Six Unapproved Peptides Despite FDA Staff Opposition
No human trials, unknown long-term effects, and a plan to loosen the rules anyway
Mark
So what actually changed on Wednesday?
Mimi
Kennedy's office released a draft that would let compounding pharmacies prepare six peptides the FDA hasn't approved. A two-week comment period follows formal publication.
Mark
Why does it matter that it came from his office?
Mimi
Normally the FDA drives something like this. Here the draft came from the health secretary's office instead, which the reporting calls unusual.
Luke
Worth being careful there. We know the origin is unusual. We don't know why, and the FDA hasn't commented yet.
Mark
There was an advisory panel vote, right?
Mimi
In July, the panel voted to loosen restrictions on the six peptides. FDA staff recommended against it.
Luke
So the plan has support from one body and opposition from another. Neither side's reasoning is detailed in the reporting, so I wouldn't say more than that.
Mark
And the safety question?
Mimi
Experts say there are no human clinical trials and the long-term effects are unknown.
Luke
That's a statement about missing evidence, not proof of harm. Unknown cuts both ways, and the piece doesn't claim injuries.
Mark
Why are teens in this story?
Mimi
Peptides are popular on TikTok, especially among boys, tied to muscle-building claims and trends like looksmaxxing. Those claims are unproven.
Luke
Right, and the reporting doesn't give usage numbers. Popular online isn't the same as measured.
El Pulso
- A draft from the health secretary's office would let pharmacies mix six unapproved peptides, bypassing the regulator that usually leads such changes.
- FDA staff recommended against the loosening, while an advisory panel had voted for it in July, exposing a sharp rift inside the agency.
- Peptides like BPC-157 and TB-500 are already circulating online in 'stacks' sold by influencers, with teenagers on TikTok drawn in by claims of muscle and healing.
- Experts warn that no human clinical trials exist and long-term effects are unknown, so the public comment window now becomes the arena for that argument.
- A two-week comment period follows formal publication, and the FDA's response will determine whether this draft becomes practice.
In the quiet machinery of the US Federal Register, a proposal has taken shape that would let compounding pharmacies prepare six peptides the Food and Drug Administration has never approved. It is a moment that sits at the meeting point of two old human impulses: the wish to heal faster and look younger, and the long-standing discipline of testing what we put into our bodies before we trust it. Its origin inside the health secretary's office rather than the regulator meant to shape such rules marks it as a choice of leadership, not a slow consensus, and it arrives as the wider world already sells these substances to people seeking quick promises. What remains unsettled is whether faith in a messenger molecule can be translated into safety without the human trials that would tell us what it truly does.
On Wednesday, a notice appeared in the US Federal Register describing a plan from Health Secretary Robert F Kennedy Jr. that would allow compounding pharmacies to prepare six peptides the Food and Drug Administration has never approved. Once it is formally published later this week, a two-week public comment period will open.
What stands out is how the proposal came to exist. It originated in the health secretary's own office rather than at the FDA, the agency that would normally shape a change like this. The regulator's own internal split is stark: an advisory panel voted in July to loosen restrictions, while FDA staff recommended against it. The BBC has asked the FDA for comment.
Five of the six substances are named: BPC-157, TB-500, KPV, MOTS-c and Semax. Kennedy has called himself a 'big fan' of them and has promised before to ease limits imposed under the Biden administration.
Peptides are not new. They are short chains of amino acids that the body uses as messengers, and medicine has relied on them for over a century, insulin among them. What has changed is the unregulated market that grew up around them alongside GLP-1 weight-loss drugs. Influencers sell combinations called 'stacks' with unproven promises about youth and healing, and the trend has spread among teenagers on TikTok, especially boys chasing muscle.
Health experts have warned against using these drugs, pointing above all to the absence of human clinical trials and the unknown long-term effects. The coming weeks will show whether the formal process answers that concern or simply moves past it.
On Wednesday, a notice appeared in the US Federal Register laying out a plan from Health Secretary Robert F Kennedy Jr. that would let compounding pharmacies prepare six peptides the Food and Drug Administration has never approved. Once the plan is formally published later this week, a two-week public comment period will begin.
The route the proposal took is unusual. The draft came from the health secretary's own office rather than from the FDA, the agency that would ordinarily originate a change of this kind. The BBC has contacted the FDA for comment.
Five of the six substances are named in the plan: BPC-157, TB-500, KPV, MOTS-c and Semax. Under the proposal, compounding pharmacies would be able to mix them into medications. The plan arrives after a split inside the agency. An FDA advisory panel voted in July to loosen restrictions on the six peptides, but FDA staff members recommended against doing so.
Kennedy has made his view plain. He has described himself as a "big fan" of the drugs and has previously promised to ease restrictions on them, after the Biden administration clamped down on the growing industry.
Peptides themselves are not exotic. They are short chains of amino acids, small proteins that the body makes naturally. They work as messengers, telling cells what to do, and they play roles in skin health, the immune system and hormone regulation. Medicine has used them to treat conditions for more than a century. Insulin, one of the first peptide hormones discovered, helps people with Type 1 diabetes, and some with Type 2, manage their blood sugar.
What has changed is the market around them. Unregulated peptides have surged into the wellness world since GLP-1 weight loss drugs became mainstream. Online influencers sell them in combinations they call "stacks," promoting unproven uses: looking younger, healing faster, improving skin. They have also caught on among teenagers on TikTok, especially boys, who have been drawn by unproven claims that the substances help build muscle, as part of online trends known as "biohacking" and "looksmaxxing."
Health experts have cautioned against using these drugs. Their concerns are specific: there are no clinical trials in humans, and the long-term effects are unknown.
The next steps are procedural but telling. Watch for the formal publication, the two-week comment period, any response from the FDA, and how medical experts press the point about missing human data.
Citas Notables
Kennedy has described himself as a "big fan" of the drugs.— Robert F Kennedy Jr., as reported by BBC News
Quieres la nota completa?
Lee el original en BBC News ↗
Health & Medicine